Consensus Statement on Managing Anxiety and Depression in Individuals with Inflammatory Bowel Disease.

IBD anxiety depression inflammatory bowel disease screening treatment

Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
22 Aug 2024
Historique:
received: 29 02 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: aheadofprint

Résumé

Studies have found a higher risk of comorbid anxiety and depression among patients with inflammatory bowel disease (IBD) compared with healthy individuals. If left untreated, comorbid depression and anxiety in patients with IBD can lead to poorer health outcomes and an increased healthcare utilization. The goal of this work was to develop a consensus statement to begin to address patient and provider needs and responsibilities related to screening and treatment of depression and anxiety symptoms among patients with IBD. A literature scan was conducted to gather evidence-based background information and recommendations on the screening, diagnosis, and treatment of anxiety and depression in patients with IBD. This was followed by the engagement of a panel of IBD and mental health experts and patient advocates using a modified Delphi process to synthesize the literature and distill the information into a core set of statements to support provider actions and care delivery. Six statements were distilled from the literature and consensus process that link to the general management, screening, and treatment of anxiety and depression in patients with IBD. Mental healthcare and support for IBD patients is critical; the statements included in this article represent practical considerations for IBD healthcare professionals in addressing key issues on provider awareness, knowledge and behaviors, screening and treatment resources, and patient education. This work aimed to develop a consensus statement on screening and treatment of anxiety and depression in individuals with inflammatory bowel disease. A literature scan was conducted, and an expert panel developed practical statements to guide inflammatory bowel disease healthcare professionals.

Sections du résumé

BACKGROUND BACKGROUND
Studies have found a higher risk of comorbid anxiety and depression among patients with inflammatory bowel disease (IBD) compared with healthy individuals. If left untreated, comorbid depression and anxiety in patients with IBD can lead to poorer health outcomes and an increased healthcare utilization. The goal of this work was to develop a consensus statement to begin to address patient and provider needs and responsibilities related to screening and treatment of depression and anxiety symptoms among patients with IBD.
METHODS METHODS
A literature scan was conducted to gather evidence-based background information and recommendations on the screening, diagnosis, and treatment of anxiety and depression in patients with IBD. This was followed by the engagement of a panel of IBD and mental health experts and patient advocates using a modified Delphi process to synthesize the literature and distill the information into a core set of statements to support provider actions and care delivery.
RESULTS RESULTS
Six statements were distilled from the literature and consensus process that link to the general management, screening, and treatment of anxiety and depression in patients with IBD.
CONCLUSIONS CONCLUSIONS
Mental healthcare and support for IBD patients is critical; the statements included in this article represent practical considerations for IBD healthcare professionals in addressing key issues on provider awareness, knowledge and behaviors, screening and treatment resources, and patient education.
This work aimed to develop a consensus statement on screening and treatment of anxiety and depression in individuals with inflammatory bowel disease. A literature scan was conducted, and an expert panel developed practical statements to guide inflammatory bowel disease healthcare professionals.

Autres résumés

Type: plain-language-summary (eng)
This work aimed to develop a consensus statement on screening and treatment of anxiety and depression in individuals with inflammatory bowel disease. A literature scan was conducted, and an expert panel developed practical statements to guide inflammatory bowel disease healthcare professionals.

Identifiants

pubmed: 39173019
pii: 7739104
doi: 10.1093/ibd/izae151
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CCF
ID : 0282201.354
Pays : United States

Informations de copyright

© 2024 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Auteurs

Laurie Hinnant (L)

Health Practice Area, RTI International, Research Triangle Park, NC, USA.

Nicholas Rios Villacorta (N)

Health Practice Area, RTI International, Research Triangle Park, NC, USA.

Eliza Chen (E)

Health Practice Area, RTI International, Research Triangle Park, NC, USA.

Donna Bacchus (D)

College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX, USA.

Jennifer Dotson (J)

Division of Gastroenterology, Hepatology and Nutrition, The Research Institute, Nationwide Children's Hospital, Columbus, OH, USA.
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.

Ruby Greywoode (R)

Division of Gastroenterology, Montefiore Medical Center, Bronx, NY, USA.

Laurie Keefer (L)

Icahn School of Medicine, Mount Sinai, New York, NY, USA.

Stephen Lupe (S)

Department of Gastroenterology, Hepatology & Nutrition, Cleveland Clinic, Cleveland, OH, USA.

Leah Maggs (L)

Patient Advocate, Seattle, WA, USA.

Garrett Meek (G)

Patient Advocate, Boulder, CO, USA.

Eva Szigethy (E)

Pediatric Psychiatry, Akron Children's Hospital, Akron, OH, USA.
Department of Pediatrics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Katheryn Tomasino (K)

Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Orna G Ehrlich (OG)

National Headquarters, Crohn's & Colitis Foundation, New York, NY, USA.

Sylvia Ehle (S)

National Headquarters, Crohn's & Colitis Foundation, New York, NY, USA.

Classifications MeSH